GcMAF Treatment - The Science

Click to download as PDF

Treatment with GcMAF

The main approach with GcMAF treatment is to saturate the body with unnaturally large doses of GcMAF, using a combination of individually appropriate routes. Available routes are orally, rectally, nebulization into the lungs, and injection sites [usually into the muscle, the tumour or the lymphatic system]. We also use Sonoporation [using low frequency, high power, ultrasound to increase tumour membrane permeability] to increase intracellular drug/molecule uptake. (Lentacker I, 2014 Jun).

History of GcMAF

GcMAF was discovered in 1988 by Molecular Biologist, Dr Marco Ruggiero, whilst working at The National Cancer Institute in Texas, and he collaborated on the first article published on the subject in 1990 (Pierce JH, 1990 Aug). Since then, over 59 research articles have been published and most can be viewed at the US Public Library of Medicine (www.pubmed.com).

Known Actions of GcMAF

  1. Activates Macrophages [white blood cells] that eat cancer cells (Ruggiero M P. S., 2013 Aug 22-27).
  2. Inhibits cancer cell-induced blood supply to tumours (Pacini S M. G., 2012 Jul-Aug).
  3. Inhibits cancer cell proliferation and metastatic potential (Ruggiero M P. S., 2013 Aug 22-27).
  4. Turns cancer cells back into healthy cells [reverts phenotype] (Ruggiero M P. S., 2013 Aug 22-27).
  5. Induces apoptosis [suicide of cancer cells] (Ruggiero M P. S., 2013 Aug 22-27).
  6. Suppresses HER2 oncogene expression in human breast cancer (Ruggiero M B. J., 2014 October 6-10).
  7. Repairs and grows new human neurons [neurogenesis] (Morucci G F. M., 2013) (Smith R, 2013).
  8. Increases cellular energy [mitochondrial level] (Smith R, 2013).
  9. Normalizes endocannabinoid gene expression (Siniscalco D, 2014 April).
  10. Induces the synthesis and release of Nitric Oxide by activated macrophages (Ruggiero M G. M., 2014 Sept 18-20).
  11. Counteracts the neuronal damage induced by Oxaliplatin [Chemotherapy] (Morucci G B. J., 2015 Feb).
  12. Activates osteoclasts, which are responsible for resorption of bone (Swamy N, 2001).

Clinical use of GcMAF

GcMAF treatments and their efficacy or lack thereof has not been supported by double-blind placebo randomised controlled trials. However, positive results of varying degrees, in clinical cases, have been published in peer reviewed literature, as in the cases below.
  1. Amyotrophic lateral sclerosis:
    • 1 patient (Thyer L W. E., 2013 Aug 20)
  2. Autism:
    • 40 patients (Bradstreet J, 2012 Dec 10)
    • 1 patient (Thyer L W. E., 2013 Aug 20)
  3. Brain Cancer:
    • 1 patient (Thyer L W. E., 2013 Aug)
  4. Breast cancer:
    • 2 patients (Thyer L W. E., 2013 Aug)
    • 1 patient (Thyer L W. E., 2013 Aug 20)
    • 5 patients (Ward E, 2014 Mar 8)
    • 1 patient (Inui T M. K., 2014 Aug)
  5. Bladder cancer:
    • 3 patients (Thyer L W. E., 2013 Aug)
  6. Chronic Fatigue Syndrome
    • 1 patient (Thyer L W. E., 2013 Aug 20)
  7. Colorectal cancer:
    • 1 patient (Thyer L W. E., 2013 Aug)
    • 2 patients (Ward E, 2014 Mar 8)
  8. Head/Neck squamous cell cancer:
    • 1 patient (Thyer L W. E., 2013 Aug)
  9. HIV / AIDS:
    • 8 patients (Pacini S P. T., 2011)
  10. Larynx cancer:
    • 1 patient (Thyer L W. E., 2013 Aug)
  11. Liver cancer
    • 1 patient (Inui T K. D., 2013 Jul)
  12. Lymphoma follicular:
    • 1 patient (Thyer L W. E., 2013 Aug)
  13. Lymphoma:
    • 1 patient (Thyer L W. E., 2013 Aug)
  14. Melanoma:
    • 1 patient (Ward E, 2014 Mar 8)
  15. Multiple Myeloma
    • 1 patient (Ward E, 2014 Mar 8)
  16. Multiple Sclerosis:
    • 1 patient (Thyer L W. E., 2013 Aug 20)
  17. Ovarian cancer:
    • 3 patients (Thyer L W. E., 2013 Aug)
  18. Pancreatic cancer:
    • 2 patients (Thyer L B. J., 2014 Oct 6-10)
  19. Prostate cancer:
    • 3 patients (Thyer L W. E., 2013 Aug)
    • 2 patients (Thyer L W. E., 2013 Aug 20)
    • 1 patient (Inui T K. D., 2013 Jul)
  20. Renal carcinoma:
    • 1 patient (Ward E, 2014 Mar 8)
  21. Squamous cell cancer:
    • 1 patient (Thyer L W. E., 2013 Aug)
  22. Thymic cancer:
    • 1 patient (Inui T K. D., 2013 Jul)
  23. Thyroid cancer:
    • 1 patient (Ward E, 2014 Mar 8)
  24. Tongue squamous cell cancer:
    • 2 patients (Thyer L W. E., 2013 Aug)

Safety of GcMAF

GcMAF is a naturally occurring protein which is made by the body and found in healthy people. Experience gained so far indicates that unnaturally large doses are well tolerated, however we do not know if GcMAF treatment might have a risk of complications, ranging from non-drug effects, to life threatening situations resulting in death; as no safety studies have been concluded. A safety study by the U.S. National Institutes of Health, is however currently proceeding. (GovtUS, 2015)


Bradstreet J, V. E. (2012 Dec 10). Initial Observations of Elevated Alpha-N-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections. Autism Insights, 31-38.

GovtUS, N. I. (2015, May 27). Safety Study of GcMAF (Globulin Component Macrophage Activating Factor) in Subjects With Advanced Solid Tumors. Retrieved from Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02052492

Inui T, K. D. (2013 Jul). Clinical experience of integrative cancer immunotherapy with GcMAF. Anticancer Research, 2917-2919.

Inui T, M. K. (2014 Aug). Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy. Anticancer Research, 4589-4593.

Lentacker I, D. C. (2014 Jun). Understanding ultrasound induced sonoporation: definitions and underlying mechanisms. Advanced Drug Delivery Reviews, 49-64.

Morucci G, B. J. (2015 Feb). Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin. Anti-cancer drugs, 197-209.

Morucci G, F. M. (2013). Vitamin D binding protein-derived macrophage activating factor stimulates proliferation and signalling in a human neuronal cell line. Italian Journal of Anatomy and Embryology, DOI: http://dx.doi.org/10.13128/IJAE-14897.

Pacini S, M. G. (2012 Jul-Aug). Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling. Journal of Nephrology, 577-581.

Pacini S, P. T. (2011). Macrophages of the mucosa-associated lymphoid tissue (MALT) as key elements of the immune response to vitamin D binding protein-macrophage activating factor. Italian Journal of Anatomy and Embryology.

Pierce JH, D. M. (1990 Aug). Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA. Proceedings of the National Academy of Sciences USA, 5613–5617.

Ruggiero M, B. J. (2014 October 6-10). Glycosylated Oleic Acid/Vitamin D Binding Protein Suppresses HER2 Oncogene Expression In Human Breast Cancer. Abstracts of the 9th International Conference of Anticancer Research (pp. 5845-5847). Porto Carras, Sithonia, Greece: Anticancer Research.

Ruggiero M, G. M. (2014 Sept 18-20). Intra-tumoural nitric oxide release by macrophages activated by Gc-protein-derived Macrophage Activating Factor (GcMAF). 68° Congresso della Società Italiana di Anatomia e Istologia (p. 170). Anacona: Italian Journal of Anatomy and Embryology.

Ruggiero M, P. S. (2013 Aug 22-27). Multifaceted immunotherapeutic effects of vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells. 15th International Congress of Immunology (ICI). Milan, Italy: Frontiers. Translational immunology and immune intervention.

Siniscalco D, B. J. (2014 April). The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages. Journal of Neuroinflammation.

Smith R, T. L. (2013). Effects of Gc-Macrophage Activating Factor in Human Neurons; Implications for Treatment of Chronic Fatigue Syndrome. American Journal of Immunology, 120-129.

Swamy N, G. S. (2001). Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. Journal of Cellular Biochemistry, 535-546.

Thyer L, B. J. (2014 Oct 6-10). Clinical experience of immunotherapy based on oleic acid bound to glycosylated vitamin d-binding protein in localised and metastatic adenocarcinoma of the pancreas. Anticancer Research, 5847 - 5849.

Thyer L, W. E. (2013 Aug 20). Therapeutic Effects of Highly Purified De-Glycosylated GcMAF in the Immunotherapy of Patients with Chronic Diseases. American Journal of Immunology, 78-84.

Thyer L, W. E. (2013 Aug). GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients. OncoImmunology, e25769-1-7.

Ward E, S. R. (2014 Mar 8). Clinical Experience of Cancer Immunotherapy integrated with Oleic Acid complexed with de-glycoslated Vitamin D Binding Protein. American Journal of Immunology, 23-32.